AAVantgarde raised $141 million in a Series B round co‑led by Schroders Capital alongside Atlas Venture and Forbion to advance two pivotal programs targeting inherited retinal diseases. The financing supports AAVB‑039 for Stargardt disease and AAVB‑081 for retinitis pigmentosa secondary to Usher 1B, both addressing high unmet need in early‑onset vision loss. The round attracted strategic investors including Amgen Ventures and others, enabling the firm to accelerate clinical proof‑of‑concept and expand natural history studies. AAVantgarde emphasized platform innovations—AAV8 intein‑mediated delivery—designed to overcome payload and tropism limitations in retinal gene therapy.